Literature DB >> 12727373

Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections.

Rafael Pellegrino1, Umberto Galvalisi, Paola Scavone, Vanessa Sosa, Pablo Zunino.   

Abstract

Proteus mirabilis is a common cause of urinary tract infection (UTI) and produce several types of different fimbriae, including mannose-resistant/Proteus-like fimbriae, uroepithelial cell adhesin (UCA), and P. mirabilis fimbriae (PMF). Different authors have related these fimbriae with different aspects of P. mirabilis pathogenesis, although the precise role of fimbriae in UTI has not yet been elucidated. In this work we expressed and purified recombinant structural fimbrial proteins of these fimbriae (MrpA, UcaA, and PmfA) and assessed their role as protective antigens using an ascending and a haematogenous model of UTI in the mouse. MrpA protected subcutaneously immunised mice in both models, suggesting that it could be taken into account as a promising vaccine candidate against P. mirabilis UTI. UcaA could also be an interesting subunit to be studied although it only protected mice that were challenged intravenously. All subunits elicited a strong specific serum IgG response but there was no significant correlation between antibody levels and protection. Only PmfA-immunised mice elicited a significant urinary antibody response but this protein was unable to confer protection against P. mirabilis experimental challenges. These results may contribute to the development of vaccines against P. mirabilis, an important cause of complicated UTI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727373     DOI: 10.1016/S0928-8244(03)00103-2

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  17 in total

Review 1.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

2.  Transcriptional analysis of the MrpJ network: modulation of diverse virulence-associated genes and direct regulation of mrp fimbrial and flhDC flagellar operons in Proteus mirabilis.

Authors:  Nadine J Bode; Irina Debnath; Lisa Kuan; Anjelique Schulfer; Maureen Ty; Melanie M Pearson
Journal:  Infect Immun       Date:  2015-04-06       Impact factor: 3.441

3.  Distinct Residues Contribute to Motility Repression and Autoregulation in the Proteus mirabilis Fimbria-Associated Transcriptional Regulator AtfJ.

Authors:  Nadine J Bode; Kun-Wei Chan; Xiang-Peng Kong; Melanie M Pearson
Journal:  J Bacteriol       Date:  2016-07-13       Impact factor: 3.490

Review 4.  Pathogenesis of Proteus mirabilis Infection.

Authors:  Chelsie E Armbruster; Harry L T Mobley; Melanie M Pearson
Journal:  EcoSal Plus       Date:  2018-02

5.  Zinc uptake contributes to motility and provides a competitive advantage to Proteus mirabilis during experimental urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

6.  Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; C Virginia Lockatell; David E Johnson; M Chelsea Lane; John W Warren; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 7.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 8.  Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis.

Authors:  Chelsie E Armbruster; Harry L T Mobley
Journal:  Nat Rev Microbiol       Date:  2012-10-08       Impact factor: 60.633

9.  Outer membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

Review 10.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.